Regen BioPharma
4700 Spring Street
Suite 304
La Mesa
California
91942
United States
Tel: 619-702-1404
Fax: 619-330-2328
Website: http://www.regenbiopharma.com/
169 articles about Regen BioPharma
-
Regen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023
1/9/2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.
-
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
12/19/2022
Regen BioPharma, Inc. and As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
12/12/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on December 14, 2022.
-
Regen BioPharma Appoints Two New Scientific Advisory Board Members
12/7/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced that Dr. Ravinder Reddy, a Professor of Radiology at the University of Pennsylvania and Dr. Mohammad Haris, an Associate Professor at the University of Pennsylvania have joined its Scientific Advisory Board.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022
11/28/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs) will be presenting at the Emerging Growth Conference on November 30, 2022.
-
Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
11/18/2022
The company announced the first phase of the set of in vitro experiments designed to accomplish this validation was successful.
-
Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic
11/10/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)has recently discussed the use of CAR-T therapies in cancer treatment.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022
11/2/2022
Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) will be presenting at the Emerging Growth Conference on November 9, 2022 (https://emerginggrowth.com/conference/).
-
Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space
10/26/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T therapies currently being utilized in the treatment of cancers.
-
Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
10/5/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled " Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the United States Patent and Trademark Office.
-
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
-
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy
9/19/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled "Dual Checkpoint Inhibitor Aptamer Based Therapeutics".
-
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
9/13/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a series of phased experiments to begin the process of moving its CAR-T cell de-differentiation approach through pre-clinical validation.
-
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
8/25/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T cell called "chimeric antigen receptor" (CAR) T cell.
-
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
8/11/2022
Regen BioPharma, Inc. announced the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company's novel approach for enabling chimeric antigen receptor -T cell-based therapies to kill solid tumors through prevention of a process called "T cell exhaustion".
-
Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine
7/26/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), announced today the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.
-
Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio
3/16/2022
Regen BioPharma, Inc. has an extensive intellectual property portfolio consisting of granted patents, published applications and pending applications.
-
Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies
3/10/2022
Regen BioPharma, Inc. announced a program to accelerate the clinical development of its NR2F6 therapies.
-
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
2/14/2022
Oncology Pharma, Inc. announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen's patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES.
-
Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology
2/11/2022
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein.